Cargando…

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines

Background: There is a small amount of immunological data on COVID-19 heterologous vaccination schedules in humans. We assessed the immunogenicity of BNT162b2 (Pfizer/BioNTech) administered as a second dose in healthcare workers primed with ChAdOx1-S (Vaxzevria, AstraZeneca). Methods: 197 healthcare...

Descripción completa

Detalles Bibliográficos
Autores principales: Vallée, Alexandre, Vasse, Marc, Mazaux, Laurence, Bonan, Brigitte, Amiel, Carline, Zia-Chahabi, Sara, Chan-Hew-Wai, Aurélie, Farfour, Eric, Camps, Eve, Touche, Pauline, Barret, Flavie, Parquin, François, Zucman, David, Fourn, Erwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432244/
https://www.ncbi.nlm.nih.gov/pubmed/34501264
http://dx.doi.org/10.3390/jcm10173817
_version_ 1783751120210886656
author Vallée, Alexandre
Vasse, Marc
Mazaux, Laurence
Bonan, Brigitte
Amiel, Carline
Zia-Chahabi, Sara
Chan-Hew-Wai, Aurélie
Farfour, Eric
Camps, Eve
Touche, Pauline
Barret, Flavie
Parquin, François
Zucman, David
Fourn, Erwan
author_facet Vallée, Alexandre
Vasse, Marc
Mazaux, Laurence
Bonan, Brigitte
Amiel, Carline
Zia-Chahabi, Sara
Chan-Hew-Wai, Aurélie
Farfour, Eric
Camps, Eve
Touche, Pauline
Barret, Flavie
Parquin, François
Zucman, David
Fourn, Erwan
author_sort Vallée, Alexandre
collection PubMed
description Background: There is a small amount of immunological data on COVID-19 heterologous vaccination schedules in humans. We assessed the immunogenicity of BNT162b2 (Pfizer/BioNTech) administered as a second dose in healthcare workers primed with ChAdOx1-S (Vaxzevria, AstraZeneca). Methods: 197 healthcare workers were included in a monocentric observational study in Foch hospital, France, between June and July 2021. The main outcome was the immunogenicity measured by serum SARS-CoV-2 IgG antibodies. Results: 130 participants received the ChAdOx1-S/BNT vaccine and 67 received the BNT/BNT vaccine. The geometric mean of IgG antibodies was significantly higher in the BNT/BNT vaccine group compared to the ChAdOx1-S/BNT vaccine group, namely 10,734.9, 95% CI (9141.1–12,589.3) vs. 7268.6, 95% CI (6501.3–8128.3), respectively (p < 0.001). However, after adjustment for time duration between the prime and second vaccinations, no significant difference was observed (p = 0.181). A negative correlation between antibody levels and time duration between second dose and serology test was observed for the BNT/BNT vaccine (p < 0.001), which remained significant after adjustment for all covariates (p < 0.001), but not for the ChAdOx1-S/BNT vaccine (p = 0.467). Conclusions: Heterologous and homologous schedules of ChAdOx1-S and BNT vaccines present robust immune responses after the second vaccination. The results observed were equivalent after adjustment for covariates and emphasize the importance of flexibility in deploying mRNA and viral vectored vaccines. Nevertheless, applying the ChAdOx1-S schedule vaccination for the heterologous second dose of BNT was associated with decreased IgG antibody levels compared to the homologous BNT/BNT vaccination.
format Online
Article
Text
id pubmed-8432244
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84322442021-09-11 An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines Vallée, Alexandre Vasse, Marc Mazaux, Laurence Bonan, Brigitte Amiel, Carline Zia-Chahabi, Sara Chan-Hew-Wai, Aurélie Farfour, Eric Camps, Eve Touche, Pauline Barret, Flavie Parquin, François Zucman, David Fourn, Erwan J Clin Med Article Background: There is a small amount of immunological data on COVID-19 heterologous vaccination schedules in humans. We assessed the immunogenicity of BNT162b2 (Pfizer/BioNTech) administered as a second dose in healthcare workers primed with ChAdOx1-S (Vaxzevria, AstraZeneca). Methods: 197 healthcare workers were included in a monocentric observational study in Foch hospital, France, between June and July 2021. The main outcome was the immunogenicity measured by serum SARS-CoV-2 IgG antibodies. Results: 130 participants received the ChAdOx1-S/BNT vaccine and 67 received the BNT/BNT vaccine. The geometric mean of IgG antibodies was significantly higher in the BNT/BNT vaccine group compared to the ChAdOx1-S/BNT vaccine group, namely 10,734.9, 95% CI (9141.1–12,589.3) vs. 7268.6, 95% CI (6501.3–8128.3), respectively (p < 0.001). However, after adjustment for time duration between the prime and second vaccinations, no significant difference was observed (p = 0.181). A negative correlation between antibody levels and time duration between second dose and serology test was observed for the BNT/BNT vaccine (p < 0.001), which remained significant after adjustment for all covariates (p < 0.001), but not for the ChAdOx1-S/BNT vaccine (p = 0.467). Conclusions: Heterologous and homologous schedules of ChAdOx1-S and BNT vaccines present robust immune responses after the second vaccination. The results observed were equivalent after adjustment for covariates and emphasize the importance of flexibility in deploying mRNA and viral vectored vaccines. Nevertheless, applying the ChAdOx1-S schedule vaccination for the heterologous second dose of BNT was associated with decreased IgG antibody levels compared to the homologous BNT/BNT vaccination. MDPI 2021-08-25 /pmc/articles/PMC8432244/ /pubmed/34501264 http://dx.doi.org/10.3390/jcm10173817 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vallée, Alexandre
Vasse, Marc
Mazaux, Laurence
Bonan, Brigitte
Amiel, Carline
Zia-Chahabi, Sara
Chan-Hew-Wai, Aurélie
Farfour, Eric
Camps, Eve
Touche, Pauline
Barret, Flavie
Parquin, François
Zucman, David
Fourn, Erwan
An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
title An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
title_full An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
title_fullStr An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
title_full_unstemmed An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
title_short An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
title_sort immunogenicity report for the comparison between heterologous and homologous prime-boost schedules with chadox1-s and bnt162b2 vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432244/
https://www.ncbi.nlm.nih.gov/pubmed/34501264
http://dx.doi.org/10.3390/jcm10173817
work_keys_str_mv AT valleealexandre animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT vassemarc animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT mazauxlaurence animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT bonanbrigitte animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT amielcarline animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT ziachahabisara animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT chanhewwaiaurelie animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT farfoureric animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT campseve animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT touchepauline animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT barretflavie animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT parquinfrancois animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT zucmandavid animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT fournerwan animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT valleealexandre immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT vassemarc immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT mazauxlaurence immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT bonanbrigitte immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT amielcarline immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT ziachahabisara immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT chanhewwaiaurelie immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT farfoureric immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT campseve immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT touchepauline immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT barretflavie immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT parquinfrancois immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT zucmandavid immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines
AT fournerwan immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines